ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Fujifilm taps drugmaker Takeda to speed stem cell treatments

Japanese group targets regenerative medicine after long search for drug profits

Reprogrammed cells hold the promise of regenerating diseased or injured body parts. (Photo courtesy of Kyoto University's Center for iPS Cell Research and Application)

TOKYO -- Japan's Fujifilm Holdings seeks greater speed to market for regenerative therapies that use reprogrammed cells through a partnership with Takeda Pharmaceutical, the country's biggest drugmaker.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more